In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AI drug development start-up BioXcel Therapeutics nets $55.8mm in IPO

Executive Summary

BioXcel Therapeutics Inc. (artificial intelligence (AI) platform to identify neuro and immuno-oncology drugs) netted $55.8mm in its initial public offering of 5.45mm shares at $11 (the low end of its anticipated $11-13 range for 5mm shares).

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Digital Health
    • Artificial Intelligence
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies